Ra Capital Management, L.P. Purchases 15,102 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. bought 15,102 shares of the stock in a transaction dated Friday, July 10th. The stock was purchased at an average cost of $8.97 per share, with a total value of $135,464.94. Following the completion of the purchase, the director directly owned 16,811,021 shares in the company, valued at approximately $150,794,858.37. This trade represents a 0.09% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, July 13th, Ra Capital Management, L.P. purchased 6,552 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.98 per share, with a total value of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. acquired 31,000 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. acquired 124,893 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.89 per share, with a total value of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. bought 15,414 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $8.57 per share, for a total transaction of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $7.91 per share, with a total value of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. purchased 479,039 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $6.91 per share, with a total value of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. acquired 6,510,416 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $11.52 per share, for a total transaction of $74,999,992.32.

Artiva Biotherapeutics Stock Performance

Shares of ARTV stock opened at $9.92 on Thursday. Artiva Biotherapeutics, Inc. has a 52-week low of $2.07 and a 52-week high of $14.53. The stock has a market cap of $245.22 million, a PE ratio of -2.80 and a beta of 2.18. The firm’s 50 day moving average price is $8.96 and its two-hundred day moving average price is $7.06.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, sell-side analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ARTV shares. HC Wainwright upped their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Needham & Company LLC restated a “buy” rating and set a $41.00 target price on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Wedbush boosted their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Finally, Wall Street Zen downgraded shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $39.00.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of hedge funds have recently modified their holdings of ARTV. Bank of America Corp DE increased its holdings in Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares in the last quarter. Prelude Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the third quarter valued at about $41,000. Dimensional Fund Advisors LP acquired a new position in shares of Artiva Biotherapeutics during the first quarter worth about $131,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Artiva Biotherapeutics during the fourth quarter worth about $91,000. Finally, Sanctuary Advisors LLC bought a new position in shares of Artiva Biotherapeutics during the first quarter worth about $139,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.